أوسيمرتينيب المعياري

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor used primarily for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations, including T790M.It is effective in both first-line therapy and in patients who have developed resistance to earlier EGFR inhibitors.